[MINNEAPOLIS] Novartis AG's Zolgensma, a gene therapy under review for treating children with a rare inherited disease that typically kills before the age of 2, also appears promising for a...

[LOS ANGELES] Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into...